Abstract
Leukemia is a life threatening disease that has become increasingly common. Many categories of anti-leukemic agents have been developed by probing into the nature of leukemia. Nevertheless, the needs for potent molecules with few side effects are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been developed for the advantage of relatively high efficiency and safety in the anticancer chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain insight into HDACIs’ potential as anti-leukemic agents.
Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.
Current Medicinal Chemistry
Title:Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents
Volume: 22 Issue: 17
Author(s): Jiang Bian, Lihui Zhang, Yantao Han, Chunbo Wang and Lei Zhang
Affiliation:
- ,0
Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.
Abstract: Leukemia is a life threatening disease that has become increasingly common. Many categories of anti-leukemic agents have been developed by probing into the nature of leukemia. Nevertheless, the needs for potent molecules with few side effects are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been developed for the advantage of relatively high efficiency and safety in the anticancer chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain insight into HDACIs’ potential as anti-leukemic agents.
Export Options
About this article
Cite this article as:
Bian Jiang, Zhang Lihui, Han Yantao, Wang Chunbo and Zhang Lei, Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents, Current Medicinal Chemistry 2015; 22(17) . https://dx.doi.org/10.2174/0929867322666150416094720
DOI https://dx.doi.org/10.2174/0929867322666150416094720 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Synthesis and Cytotoxicity Assessment of Novel 7-O- and 14-O-Derivatives of Glaucocalyxin A
Anti-Cancer Agents in Medicinal Chemistry Novel Molecular Targets in Cancer Chemotherapy Waiting for Discovery
Current Medicinal Chemistry - Anti-Cancer Agents Spectrum of Radiopharmaceuticals in Nuclear Oncology
Current Cancer Drug Targets Subject Index To Volume 12
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Plant Coumestans: Recent Advances and Future Perspectives in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Implication of CD154/CD40 Interaction in Healthy and Autoimmune Responses
Current Immunology Reviews (Discontinued) Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry Possibility of Enhanced Risk of Retinal Angiogenesis in Athletes with Pre- Existing Retinal Situation Abusing Erythropoietin Doping: A Hypothesis
Current Drug Safety Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals Ultrasound Assisted Synthesis of 3,4-Diyne Substituted Isocoumarin Derivatives: Identification of Potential Cytotoxic Agents
Mini-Reviews in Medicinal Chemistry The Mad2-Binding Protein p31<sup>comet</sup> as a Potential Target for Human Cancer Therapy
Current Cancer Drug Targets Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab
Recent Patents on Biotechnology The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets A Review: Hair Health, Concerns of Shampoo Ingredients and Scalp Nourishing Treatments
Current Pharmaceutical Biotechnology